A serial acquirer of life sciences and diagnostics businesses with the Danaher Business System — a perpetual compounding machine that creates value through operational excellence and recurring revenue
Pat Dorsey
Dorsey Asset Management
“Pat Dorsey: 'Danaher's competitive advantage isn't any single product — it's the Danaher Business System itself. DBS is a repeatable process for creating value in acquisitions that no competitor can replicate.'”
The Business
- Danaher Corporation is a global life sciences and diagnostics company operating through three segments: Biotechnology, Life Sciences, and Diagnostics
- Key brands include Beckman Coulter (diagnostics), Cytiva (bioprocessing), Pall (filtration), Leica Microsystems, and Aldevron (plasmid DNA/mRNA manufacturing)
- The Danaher Business System (DBS) is applied across all businesses to drive continuous improvement in quality, delivery, cost, and innovation
- FY2025: $24.6B revenue, $3.6B net income, 19% operating margin, $5.3B free cash flow with approximately 63,000 employees
Why They Own It
“Pat Dorsey: 'Danaher's competitive advantage isn't any single product — it's the Danaher Business System itself. DBS is a repeatable process for creating value in acquisitions that no competitor can replicate.'”
- The Danaher Business System is a proprietary operational excellence framework that creates value in every acquisition — a repeatable, scalable competitive advantage
- Post-spinoffs, Danaher is a pure-play life sciences and diagnostics company with ~80% recurring revenue from consumables and services
- FY2025: $24.6B revenue, $3.6B net income, $5.3B free cash flow — strong cash generation despite a post-COVID normalization year
- Dorsey, the author of 'The Little Book That Builds Wealth' on economic moats, sees Danaher's switching costs and installed base as creating a near-permanent customer lock-in
- M&A pipeline remains robust — Danaher has decades of track record acquiring and improving businesses, and life sciences fragmentation provides ample targets
What the investor sees
Danaher trades at approximately $205/share with a $150B market cap, or roughly 40x earnings and 28x free cash flow. Dorsey's thesis is that Danaher's premium is justified by the recurring nature of its revenue (~80% consumables/services), the value-creation engine of DBS, and the long runway for M&A in fragmented life sciences markets. The bioprocessing and diagnostics end markets have secular growth tailwinds from biologics, gene therapy, and precision medicine.
Financial Snapshot
$24.6B
revenue FY2025
$3.6B
net income
$5.05
eps
19%
operating margin
$5.3B
free cash flow
2.9% YoY
revenue growth
~63,000
employees
~80%
recurring revenue
The Moat
- Danaher Business System — proprietary operating excellence methodology that systematically improves every acquired business
- Switching costs — life sciences customers validate workflows on Danaher instruments; switching costs are measured in years and millions of dollars
- Installed base lock-in — large installed base of instruments generates recurring revenue from consumables, service contracts, and software
- Regulatory moat — FDA and CE-approved diagnostic instruments create high barriers to competitive displacement
- M&A expertise — 30+ years of successful serial acquisitions in fragmented life sciences markets
What Could Go Wrong
Post-COVID normalization — bioprocessing revenue declined as pandemic vaccine/therapeutic demand faded, creating a revenue headwind
High valuation — at 40x earnings, Danaher is priced for perfection with limited margin for error
M&A integration risk — future acquisitions may not generate returns comparable to historical deals
China exposure — life sciences spending in China has slowed due to anti-corruption campaigns and economic weakness
Revenue growth of only 2.9% in FY2025 raises questions about organic growth momentum
Catalysts
- Bioprocessing recovery — biologic drug approvals and pipeline growth should drive a recovery in Cytiva and Pall revenue
- M&A pipeline — fragmented life sciences market provides ample acquisition targets to drive growth
- Margin expansion through DBS — continued application of the business system drives incremental margin improvement
- Precision medicine tailwinds — gene therapy, cell therapy, and mRNA platforms require Danaher's bioprocessing and manufacturing tools
- Share buybacks — strong free cash flow generation supports share count reduction
In Their Own Words
“Pat Dorsey: 'Switching costs in life sciences are enormous. When a lab validates its workflows on Beckman Coulter instruments or Cytiva bioprocessing equipment, the cost of switching is measured in years and millions of dollars.'”
“Pat Dorsey: 'The best moats are invisible to casual observers. Danaher looks like a boring industrial conglomerate, but it's actually one of the highest-quality compounders in the world.'”